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Abstract
Basal cell carcinoma (BCC) incidence is increasing, particularly among adults under age 40. 
Pigment-related characteristics are associated with BCC in older populations, but epidemiologic 
studies among younger individuals and analyses of phenotype-genotype interactions are limited. 
We examined self-reported phenotypes and melanocortin 1 receptor gene (MC1R) variants in 
relation to early-onset BCC. BCC cases (n=377) and controls with benign skin conditions (n=390) 
under age 40 were identified through Yale’s Dermatopathology database. Factors most strongly 
associated with early-onset BCC were skin reaction to first summer sun for one hour [severe 
sunburn vs. tan odds ratio (OR)=12.27, 95% confidence interval (CI)=4.08–36.94] and skin color 
(very fair vs. olive OR=11.06, 95% CI=5.90–20.74). Individuals with two or more MC1R non-
synonymous variants were 3.59 times (95% CI=2.37–5.43) more likely to have BCC than those 
without non-synonymous variants. All host characteristics and MC1R were more strongly 
associated with multiple BCC cases status (37% of cases) than single BCC case status. MC1R, 
number of moles, skin reaction to first summer sun for one hour, and hair and skin color were 
independently associated with BCC. BCC risk conferred by MC1R tended to be stronger among 
those with darker pigment phenotypes, traditionally considered to be at low-risk of skin cancer.
Introduction
Basal cell carcinoma (BCC), which accounts for 80% of non-melanoma skin cancers 
(NMSCs), is the most common cancer in the US, with more than two million BCCs 
diagnosed annually (Rogers et al., 2010; ACS, 2011). While BCC is unlikely to metastasize 
and is associated with low mortality, morbidity associated with this disease is quite high. In 
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Corresponding Authors and Request for Reprints: Allen E. Bale, M.D.; Yale University School of Medicine; 333 Cedar Street; P.O. 
Box 208005; New Haven, CT 06520-8005; Phone: 203-785-5745; Fax: 203-785-7227; allen.bale@yale.edu. Susan T. Mayne, PhD; 
Yale School of Public Health; 60 College Street, P.O. Box 208034; New Haven, CT 06520-8034; Phone: 203-785-6274; Fax: 
203-785-6980; susan.mayne@yale.edu.¶Joint senior authors. These individuals contributed equally to this work and are listed in alphabetical order.
Conflict of Interest
The authors state no conflict of interest.
HHS Public Access
Author manuscript
J Invest Dermatol. Author manuscript; available in PMC 2012 October 01.
Published in final edited form as:
J Invest Dermatol. 2012 April ; 132(4): 1272–1279. doi:10.1038/jid.2011.402.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
1992 among US Medicare beneficiaries, NMSC ranked among the top five most costly 
cancers to treat (Housman et al., 2003). Newer data indicate from 1992 to 2006 in the 
Medicare population, there was a 77% increase in the total number of skin cancer-related 
procedures (93.7% NMSC), due to an increase in the number of individuals with these 
malignancies (Rogers et al., 2010). In recent decades, BCC incidence has increased (Arits et 
al., 2011; Bath-Hextall et al., 2007; Birch-Johansen et al., 2010; Doherty et al., 2010; Flohil 
et al., 2011; Karagas et al., 1999; Levi et al., 2001), with notable increases among adults 
under the age of 40, particularly women (Bath-Hextall et al., 2007; Birch-Johansen et al., 
2010; Christenson et al., 2005).
Ultraviolet (UV) radiation is the primary environmental etiologic factor for BCC, yet 
intrinsic or host factors, including pigment-related characteristics, are also likely to play a 
role in carcinogenesis in conjunction with UV (reviewed in (Dessinioti et al., 2010; Madan 
et al., 2010)). Among pigment-related factors, the melanocortin 1 receptor gene (MC1R), 
which encodes a protein that binds melanocyte-stimulating hormone and regulates skin and 
hair pigmentation (Valverde et al., 1995), has received considerable attention and has been 
associated with an increased risk of melanoma and BCC (reviewed in (Scherer and Kumar, 
2010)). Even though MC1R variants are related to light pigmentation phenotypes (Bastiaens 
et al., 2001; Box et al., 2001; Dwyer et al., 2004; Han et al., 2006; Kanetsky et al., 2004; 
Kennedy et al., 2001; Koppula et al., 1997; Naysmith et al., 2004; Palmer et al., 2000; 
Smith et al., 1998; Valverde et al., 1995), there seems to be an effect of genotype 
independent of phenotype on both BCC (Bastiaens et al., 2001; Box et al., 2001; Dwyer et 
al., 2004; Han et al., 2006; Liboutet et al., 2006; Scherer et al., 2008) and melanoma 
(Dwyer et al., 2004; Kanetsky et al., 2010; Kennedy et al., 2001; Landi et al., 2005; Palmer 
et al., 2000). These findings, in combination with other emerging evidence from 
epidemiologic, clinical, and basic science research, indicate BCC may be more similar to 
melanoma than squamous cell carcinoma (SCC) in etiology (Dessinioti et al., 2010; Madan 
et al., 2010).
BCC has been relatively understudied in epidemiologic research because it is not reported to 
most cancer registries. Thus far, two studies provided an intriguing glimpse at risk factors 
for early-onset BCC, but these had small sample sizes; 30 cases (Boyd et al., 2002) and 25 
cases (Bakos et al., 2011). Due to the limited understanding of early-onset BCC etiology, we 
conducted a case-control study in Connecticut among individuals under age 40 investigating 
lifestyle, environmental, and genetic factors. The rationale for this study was multifold and 
included increasing incidence among young people, the opportunity to evaluate genetic 
factors in a genetically enriched population, the potential for younger individuals to better 
recall early-life exposures, and a growing prevalence of indoor (IARC, 2007) and outdoor 
tanning.
Here, we describe the design of the Yale Study of Skin Health in Young People and the 
associations between host phenotype characteristics and MC1R in relation to early-onset 
BCC. We also evaluated potential variation in the association between MC1R and BCC by 
phenotype.
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Results
Sixty-nine percent of the 767 participants were female (257 cases, 274 controls). The mean 
age at skin biopsy in cases was 35.1 years (SD=4.6) and 34.7 years (SD=5.5) in controls. 
Among cases, 54.1% (n=204) had the referent BCC on the head or neck, followed by 101 
(26.8%) with a trunk BCC, and 72 (19.1%) with a BCC on an extremity. Approximately 
37% (n=140) of cases had two or more BCCs under age 40.
All phenotype characteristics and MC1R were significantly associated with early-onset 
BCC, with lighter pigment phenotypes at greater risk (Table 1). The most pronounced risk 
factor was skin reaction to first summer sun of the season; those who experienced severe 
sunburn and blistering were 12.27 (95% CI=4.08–36.94) times more likely to have BCC 
than those who turned brown/tanned with no burning. Skin color was another strong risk 
factor; individuals with very fair skin were 11.06 (95% CI=5.90–20.74) times more likely to 
have BCC than those with olive skin. In a sensitivity analysis, excluding the top three 
control conditions one at a time from the control group did not impact risk estimates for all 
exposures (data not shown). Controlling for indoor and outdoor UV exposures did not alter 
associations for the characteristics of interest (data not shown).
We detected 35 MC1R variants (Supplemental Table 1 Online). Individuals with one MC1R 
non-synonymous variant were 93% more likely than those without non-synonymous 
variants to have BCC, with a stronger association for individuals with two or more non-
synonymous MC1R variants (OR=3.59, 95% CI=2.37–5.43) (Table 1). Risk was elevated for 
both “major” and “minor” red hair variants (Table 2).
All host characteristics were associated with both single and multiple BCC case status, but 
the magnitude of the risk estimates for multiple BCC was much greater (Table 1). One of the 
most pronounced differences was for skin color. While very fair skin as compared to olive 
skin was associated with a 6.62 increased risk of single BCC, the OR for multiple BCC was 
almost 5.5 times greater (OR=36.07, 95% CI=8.95–161.94).
Participants with lighter pigment characteristics, less ability to tan, and more freckles were 
more likely to have at least one non-synonymous MC1R variant as compared to those with 
darker phenotypes (Supplemental Table 2 Online).
In the mutually adjusted model, hair and skin color, MC1R, moles, and skin reaction to first 
summer sun were independently associated with BCC (Table 3). Very fair skin was 
associated with a 4.48 fold independent increased risk of BCC compared to olive skin 
(OR=4.48, 95% CI=2.21–9.09) and individuals with two or more non-synonymous variants 
had a 91% independent increased risk compared to those with no variants (OR=1.91, 95% 
CI=1.20–3.03).
While there was no evidence of significant interactions between phenotypes and MC1R in 
relation to BCC risk, we observed some general patterns in risk across strata (Table 4). The 
association between MC1R and BCC was stronger among individuals with darker 
phenotypes including, darker eye and skin color, fewer moles and freckles, and tanning 
rather than burning with sun exposure.
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Discussion
In this case-control study of early-onset BCC, host phenotype characteristics of lighter 
pigmentation and inability to tan, as well as MC1R were independently associated with 
increased disease risk. To our knowledge, a large-scale epidemiologic study focused 
exclusively on BCC among young adults has not been previously reported. In our unique 
population, the magnitudes of risk associated with phenotype characteristics often associated 
with BCC were generally magnified as compared to studies in older individuals (Dessinioti 
et al., 2010; Hogan et al., 1989; Kiiski et al., 2010; Maia et al., 1995; Naldi et al., 2000; 
Vitasa et al., 1990; Zanetti et al., 1996). Although BCC is relatively rare in young people, 
37% of our cases had two or more BCCs under the age of 40, and the association with each 
of our exposures was much stronger for these cases.
Our finding of a nearly two-fold increase in BCC risk for one non-synonymous MC1R 
variant and a 3.6 fold increase for two non-synonymous variants is in agreement with other 
BCC studies (Bastiaens et al., 2001; Box et al., 2001; Dwyer et al., 2004; Han et al., 2006; 
Scherer et al., 2008). Yet, as we hypothesized, the magnitude of risk we observed was 
greater than in studies of older adults, where risk estimates have been less than or equal to 
2.6 (Bastiaens et al., 2001; Box et al., 2001; Dwyer et al., 2004; Han et al., 2006; Scherer et 
al., 2008). Of note, one small case-control study with a heterogeneous case group enrolled 
on the basis of having either familial BCC, multiple BCC, BCC with another cancer, or 
BCC before age 40, observed a seven-fold increased risk of BCC with two MC1R variants 
(Liboutet et al., 2006). Similar to our findings, MC1R variants have been associated with 
lighter pigment phenotypes in numerous studies (Bastiaens et al., 2001; Box et al., 2001; 
Dwyer et al., 2004; Han et al., 2006; Kanetsky et al., 2004; Kennedy et al., 2001; Koppula 
et al., 1997; Naysmith et al., 2004; Palmer et al., 2000; Smith et al., 1998; Valverde et al., 
1995).
The independent associations with early-onset BCC for MC1R, hair and skin color, moles, 
and skin reaction are in line with several studies of BCC (Bastiaens et al., 2001; Box et al., 
2001; Dwyer et al., 2004; Han et al., 2006; Liboutet et al., 2006; Scherer et al., 2008) and 
melanoma (Dwyer et al., 2004; Kanetsky et al., 2010; Kennedy et al., 2001; Landi et al., 
2005; Palmer et al., 2000). That MC1R remained an independent risk factor suggests 
variants in this gene contribute to BCC pathogenesis through mechanisms besides 
pigmentation. As a potential tumor initiator, impairment of MC1R function leads to 
synthesis of pheomelanin, which acts as a free radical generator and may cause oxidative 
DNA damage on top of the UVB-induced damage typically associated with sunlight 
exposure to fair skin (Scherer and Kumar, 2010). Furthermore, mouse studies show an effect 
of MC1R genotype on production of premalignant clones in the absence of any melanin 
pigment, suggesting a mechanism separate from pigment modulation (Robinson et al., 
2010). A role in tumor progression through regulation of cytokines and their associated 
receptors, such as NF-kB, has been suggested (Eves et al., 2003; Getting, 2006). There is a 
complex interplay between NF-kB regulation and the ability of tumor cells to escape 
immune surveillance and invade surrounding tissues.
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The association of pigment phenotypes independent of MC1R genotype points toward the 
involvement of other pigment-related genes in BCC risk. TYR, ASIP, and SLC45A2 have 
been identified in other BCC studies (Gudbjartsson et al., 2008; Nan et al., 2009; Scherer 
and Kumar, 2010; Stacey et al., 2009).
We found that MC1R was more strongly associated with early-onset BCC among those with 
darker phenotypes. Several other BCC studies have evaluated this genotype-phenotype 
interaction, but results have been inconsistent. One study observed no clear variation in the 
association of MC1R and BCC risk by hair or skin color (Han et al., 2006), while others 
found an increased risk in those with darker hair and skin, but opposite patterns for eye color 
(Liboutet et al., 2006), or suggestive increased risk among individuals with the lightest skin 
(Bastiaens et al., 2001; Scherer et al., 2008). One study of BCC (Dwyer et al., 2004) and 
several of melanoma (Dwyer et al., 2004; Ichii-Jones et al., 1998; Kanetsky et al., 2010; 
Landi et al., 2005; Palmer et al., 2000) had findings similar to ours.
Our findings, in conjunction with research in melanoma, may have applicability in primary 
prevention. Among participants with the darkest pigment phenotypes, the estimated 
etiologic fractions for carrying two or more non-synonymous MC1R variants ranged from a 
low of 12% among individuals with no freckles on the face to a high of 28% among 
individuals with brown eyes. Because people with darker phenotypes are also at risk of skin 
cancer, sun protection interventions may need to be broadened to include these individuals 
who would otherwise consider themselves low-risk.
Our study had several strengths including extensive self-report phenotype data from a face-
to-face interview and MC1R sequencing for nearly all participants. Importantly, the 
laboratory was blinded to case-control status and interviewers were blinded to case-control 
status until the end of the interview. Utilizing a centralized dermatopathology facility 
serving many dermatologists in Connecticut enabled us to identify controls most likely to 
constitute the source population of our cases; that is, young people who see a dermatologist 
for a skin lesion. Because our controls had undergone a skin biopsy, this may have reduced 
differential reporting by case status, as our controls may have been more sensitive to 
exposures concerning skin health than general population controls. Our results were robust 
in sensitivity analyses removing specific control conditions, indicating associations were not 
driven by inclusion of one benign condition.
As in any case-control study, selection bias is a potential concern. Another potential 
limitation is related to possible misclassification within participant self-reported measures of 
phenotype, as we did not have more objective measures of pigment characteristics, such as 
clinician assessment or spectroscopy, but this is most likely to be non-differential. Finally, 
although controls were seen by a dermatologist for a benign skin condition, we did not know 
if a complete skin examination was performed. Therefore, controls could have possibly had 
a BCC; however, the likelihood of this is low in our young sample.
In summary, several host phenotype characteristics and MC1R were strongly and 
independently related to early-onset BCC. In this young population, the associations 
between the exposures of interest and disease risk were more pronounced for multiple BCC, 
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and the relationship between MC1R and BCC was stronger among individuals with darker 
pigmentation phenotypes. Even persons with darker pigment phenotypes, traditionally 
considered to be low risk of skin cancer, were at substantial risk of early-onset BCC if they 
had MC1R variants. To our knowledge a large scale epidemiologic investigation of these 
characteristics in relation early-onset BCC is previously unreported, so our results need 
confirmation in other populations.
Materials and Methods
Study Design
The Yale Study of Skin Health in Young People was conducted in Connecticut between July 
2007 and December 2010. BCC cases diagnosed between July 1, 2006 and September 30, 
2010 were identified through Yale University’s Dermatopathology database. Approximately 
two-thirds of dermatologists in Connecticut send their biopsied tissue to Yale for 
dermatopathologic evaluation. Potential controls were randomly sampled from individuals 
in the database with a variety of minor benign skin conditions. To be eligible for the study, 
participants had to: be less than 40 years of age at the time of skin biopsy, reside in 
Connecticut, speak English, and themselves (or appropriate guardian for decisionally 
impaired individuals and those under age 18) be mentally and physically capable of 
completing study components. Yale University’s Institutional Review Board approved the 
study and participants (or guardians) provided written informed consent. The study was 
conducted in accordance with the Declaration of Helsinki Principles.
Potential participants were mailed a letter and study brochure. One of two study interviewers 
then contacted individuals by telephone and invited them to participate in the study. If the 
telephone number was not working (disconnected, wrong number, no number listed), 
another letter was mailed asking for updated contact information via telephone or mail. If 
the telephone number and mailing address were incorrect, updated contact information was 
sought periodically.
Among the 665 potentially eligible BCC cases identified during the study period, 17 (2.6%) 
were determined ineligible upon initial contact: 14 moved out of the state and 3 could not 
complete all study components (two non-English speakers, one severe illness). Of the 
remaining 648 individuals, 114 (17.6%) could not be contacted directly (no telephone 
number, non-working telephone number, only spoke to other person in household, left 
message only). Among the 534 cases we were able to directly reach and determine full 
eligibility, 145 (27.2%) declined to participate, resulting in 389 enrolled cases (participation 
rate=72.8%).
Cases were classified into single (only one BCC) or multiple (two or more BCCs) BCC 
under the age of 40 based on participant self-report and searching the Yale 
Dermatopathology database (records from 1990 on). A total of 242 (62.2%) cases had one 
BCC in the database and did not self-report a prior BCC and 120 (30.9%) cases had two or 
more BCCs in the database. The remaining 27 (6.9%) cases had one BCC in the database, 
but self-reported a prior BCC; these individuals were categorized as multiple cases, as this 
did not significantly alter risk estimates.
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To determine control eligibility, two dermatologists reviewed skin conditions diagnosed 
during a one-year period in persons under age 40 in the Yale Dermatopathology database. A 
variety of diagnoses were determined ineligible for sampling, including skin cancers/
precancers (e.g., melanoma, squamous cell carcinoma, T-cell lymphomas, actinic keratoses), 
potentially UV-related benign conditions (e.g., solar lentigo, abnormal nevus, erythematous 
conditions), dermal conditions treated with UV therapy (e.g., psoriasis) and pigment 
disorders (e.g., vitiligo).
Randomly sampled controls were frequency matched to BCC cases on age at biopsy (5 year 
age groups), gender, and biopsy site (head/neck, trunk, extremity). Among the 1,102 
potentially eligible controls, 60 (5.4%) were found ineligible upon initial contact (39 moved 
out of state, 10 non-English speakers, 2 did not recall having a skin biopsy, 1 hearing 
impaired, 1 hospitalized) or during the interview (7 self-reported a BCC). Of the remaining 
1,042 individuals, 288 (27.6%) could not be contacted directly. Among the 754 potential 
controls we could directly reach and determine full eligibility, 296 (39.3%) declined to 
participate and 458 controls enrolled (participation rate=60.7%). Controls had a variety of 
benign skin conditions. The three most common were cyst (16.4%), seborrheic keratosis 
(16.2%), and wart (11.4%). All other conditions were present in less than 10% of controls.
Participants completed an in-person face-to-face interview during which interviewers 
obtained information on sociodemographics, UV exposure (solar and artificial), personal 
and family medical history, and host phenotype characteristics including, self-reported eye 
color, skin color (inner upper arm), hair color (natural color), skin reaction to strong sunlight 
for the first time in the summer for one hour without sunscreen, skin reaction after repeated 
and prolonged exposure to sunlight, amount of freckles on the face (selected from a range of 
images), and number of moles on the back = 5 mm (using clear acetate size template) using 
a structured questionnaire. Interviewers were blinded to case-control status until the end of 
the interview, when personal history of cancer, including BCC, was queried.
Participants also completed several mailed self-administered questionnaires (residence 
history, outdoor jobs, attitudes toward sunless, outdoor, and indoor tanning). Interviewers 
collected buccal cells from 98.9% of participants using Oragene®•DNA 2mL saliva 
collection kits (DNA Genotek Inc.; Ontario, Canada; http://www.dnagenotek.com/
index.html) at the end of the interview following the manufacturer’s protocol, including 
rinsing the mouth with drinking water and then waiting five minute before collection.
MC1R Sequencing and Variant Classification
Oragene kits were stored at room temperature until processed. DNA was isolated based on 
the manufacturer’s protocol. Laboratory personnel were blinded to case-control status.
The MC1R gene was PCR amplified as a single 1.3 kb fragment. Each 25 μl PCR reaction 
contained 25–50 ng of DNA; 200 μmol/L dNTPs; 5 μmol/L of each primer, 5′-
ACTAAGCAGGACACCTGGAG-3′ and 5′-TCTTTAGGAGCCTGAGGTTG-3′; PC2 
buffer (50 mM Tris-HCl pH 9.1, 16 mM ammonium sulfate, 3.5 mM MgCl2, and 150 
mg/ml BSA; Ab Peptides, Inc.); 0.25 mmol/L spermidine; 0.125 units of Taq DNA 
polymerase (Amplitaq®, Roche); and 0.125 units of Taq Extender (Stratagene). PCR was 
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performed with an initial denaturation for two minutes at 97°C; followed by 35 cycles of 
denaturation at 96°C for 30 seconds, annealing at 66°C for 30 seconds, and extension for 
one minute at 72°C; and a final extension at 72°C for five minutes. PCR products were size 
fractionated on a 1.5% GPG/LETM (American Bioanalytical) agarose gel, stained with 
ethidium bromide, and photographed under ultraviolet light in order to confirm the presence 
of the correct PCR fragment.
PCR products were sequenced bidirectionally. 5 μl of the PCR products were treated with 20 
units Exonuclease I (E.coli) (New England BioLabs) and two units Shrimp Alkaline 
Phosphatase (USB). Either 0.4 μmol/L of the forward primer, 5′-
ACTAAGCAGGACACCTGGAG-3′, or the reverse primer 5′-
GGTCACACAGGAACCAGACC-3′ were added. The sequencing was carried out at Yale 
University’s W. M. Keck Facility using Applied Biosystems 3730 capillary instruments. The 
sequencing reactions utilized fluorescently-labeled dideoxynucleotides (Big Dye 
Terminators) and Taq FS DNA polymerase in a thermal cycling protocol. The sequence was 
analyzed using Sequencher 4.9 (Gene Codes Corporation) comparing the query sequence to 
the standard sequence with no variants in MC1R (NM_002386.3).
MC1R variants were classified into synonymous and non-synonymous variants. Non-
synonymous variants were grouped into “major” and “minor” red hair variants (Box et al., 
1997; Kanetsky et al., 2004; Valverde et al., 1995). We then calculated the number of total 
non-synonymous variants within the MC1R coding region.
Statistical Analysis
Analyses were limited to non-Hispanic Whites; 380 (97.7%) cases and 390 (85.2%) 
controls. Three BCC cases with Gorlin Syndrome, which predisposes individuals to multiple 
BCCs early in life (Gorlin and Goltz, 1960), were also excluded. Our analytic population 
consisted of 767 individuals (377 cases, 390 controls); three cases and three controls were 
under age 18 at enrollment.
Phenotype characteristics and MC1R (count of all non-synonymous variants within the gene, 
0, 1, ≥ 2 variants) were treated as categorical variables. We calculated odds ratios (ORs) and 
95% confidence intervals (CIs) using multivariate logistic regression for all cases. Analyses 
were then restricted to cases with only one BCC (n=237) and then cases with two or more 
BCCs (n=140). We determined independent relationships using backward stepwise 
selection; retaining only exposures statistically significant at alpha=0.05, as well as gender, 
age, and body site. Phenotype-genotype interactions were tested with cross-product terms. 
Analyses were conducted using SAS Version 9.2 (Cary, NC).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 2
Alternate classifications of MC1R variants in relation to BCC in the Yale Study of Skin Health. Referent 
group for all variables is individuals with no non-synonymous variants.
Characteristic Cases/Controls OR1 (95% CI)
No non-synonymous variants 65/131 1.00
MC1R “major” red hair variants2
 1 variant 158/108 2.88 (1.94–4.27)
 ≥ 2 variants 31/11 5.85 (2.73–12.54)
MC1R alternate “major” red hair variants3
 1 variant 147/95 2.97 (1.98–4.44)
 ≥ 2 variants 20/8 4.95 (2.04–12.00)
MC1R “minor” red hair variants4
 1 variant 147/129 2.20 (1.55–3.11)
 ≥ 2 variants 34/30 3.09 (1.88–5.07)
1 “major”2 and 1 “minor” red hair variant 63/31 3.95 (2.31–6.76)
1Adjusted for age at diagnosis (continuous), body site (head, extremity, trunk), and gender.
2
Includes D84E, R142H, R151C, I155T, R160W, and D294H.
3
Includes R151C, R160W, and D294H.
4
Includes V60L, V92M, and R163Q.
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Table 3
Mutually adjusted odds ratios (OR) and 95% confidence intervals (CIs) for the most parsimonious model of 
the association between host characteristics, MC1R, and BCC in the Yale Study of Skin Health
Characteristic Cases/Controls
Mutually adjusted
OR1 (95% CI)
Hair color
 Black/Dark brown 99/157 1.00
 Light brown 135/151 1.31 (0.78–1.64)
 Blonde/Fair 100/63 1.63 (1.04–2.53)
 Red 39/11 2.74 (1.23–6.09)
Skin color
 Olive 15/74 1.00
 Fair 211/232 2.75 (1.46–5.18)
 Very fair 147/76 4.48 (2.21–9.09)
MC1R non-synonymous variants
 0 variants 65/130 1.00
 1 variant 172/175 1.41 (0.95–2.11)
 ≥ 2 variants 136/77 1.91 (1.20–3.03)
Moles ≥ 5 mm on back
 None 172/204 1.00
 0–4 136/145 1.03 (0.73–1.44)
 5–9 42/22 1.93 (1.05–3.52)
 10 or more 23/11 2.19 (0.98–4.90)
Skin reaction with first summer sun exposure
 Turn brown, no sunburn 6/31 1.00
 Mild sunburn followed by tan 141/196 1.91 (0.73–5.03)
 Painful sunburn peeling 196/142 2.43 (0.90–6.58)
 Severe sunburn blistering 30/13 3.68 (1.11–12.23)
1Adjusted for age at diagnosis (continuous), body site (head, extremity, trunk), gender and all other characteristics in table.
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Table 4
MC1R non-synonymous variants and BCC risk stratified by host characteristics in the Yale Study of Skin 
Health
Characteristic MC1R Variants Cases/Controls OR1 (95% CI) p for interaction2
Eye color 0.557
 Brown 0 17/56 1.00
1 38/71 1.64 (0.82–3.29)
≥ 2 31/23 4.37 (1.99–9.56)
 Hazel/Green 0 17/34 1.00
1 52/48 2.06 (1.01–4.20)
≥ 2 42/26 2.99 (1.38–6.47)
 Blue/Grey 0 31/41 1.00
1 83/56 1.95 (1.08–3.53)
≥ 2 65/28 3.25 (1.67–6.35)
Hair color 0.670
 Black/Dark brown 0 23/62 1.00
1 55/72 1.94 (1.05–3.58)
≥ 2 22/23 2.62 (1.20–5.73)
 Light brown 0 24/53 1.00
1 66/69 2.00 (1.09–3.67)
≥ 2 46/30 3.12 (1.57–6.19)
 Blonde/Fair/Red 0 18/16 1.00
1 51/34 1.23 (0.54–2.80)
≥ 2 70/24 2.44 (1.05–5.65)
Skin color 0.364
 Olive/Fair 0 47/120 1.00
1 111/132 2.04 (1.32–3.14)
≥ 2 69/55 3.38 (2.04–5.59)
 Very fair 0 18/11 1.00
1 62/43 0.94 (0.39–2.25)
≥ 2 69/22 1.81 (0.72–4.52)
Skin reaction to first summer sun exposure 0.851
 Turn brown, no burn/Mild burn then tan 0 38/96 1.00
1 69/98 1.64 (1.00–2.71)
≥ 2 41/33 3.04 (1.64–5.61)
 Painful burn peeling/Severe burn blistering 0 27/34 1.00
1 104/77 1.63 (0.90–2.96)
≥ 2 97/44 2.64 (1.41–4.96)
Skin reaction to prolonged sun exposure 0.299
 Very brown/Moderately tanned 0 46/115 1.00
1 102/129 1.92 (1.24–2.99)
≥ 2 59/45 3.49 (2.04–5.95)
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Characteristic MC1R Variants Cases/Controls OR1 (95% CI) p for interaction2
 Mildly tanned peeling/Freckled, no tan 0 19/16 1.00
1 71/46 1.12 (0.51–2.45)
≥ 2 79/32 1.81 (0.81–4.03)
Moles ≥ 5 mm on back 0.496
 None 0 28/74 1.00
1 85/91 2.54 (1.48–4.35)
≥ 2 59/39 4.05 (2.20–7.47)
 0–4 0 27/52 1.00
1 55/61 1.68 (0.92–3.07)
≥ 2 55/33 3.31 (1.72–6.36)
 ≥ 5 0 10/5 1.00
1 33/23 0.51 (0.14–1.89)
≥ 2 22/5 2.26 (0.49–10.46)
Freckles on face 0.723
 None 0 28/68 1.00
1 38/60 1.55 (0.83–2.92)
≥ 2 12/8 4.33 (1.54–12.15)
 Very few 0 18/38 1.00
1 38/50 1.73 (0.83–3.59)
≥ 2 26/21 2.44 (1.06–5.61)
 Few/Some/Many 0 19/25 1.00
1 97/65 1.88 (0.95–3.75)
≥ 2 100/48 2.55 (1.26–5.15)
1Adjusted for age at diagnosis (continuous), body site (head, extremity, trunk), and gender.
2
Based on inclusion of cross-product term in multivariate model.
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